Allogene Therapeutics (ALLO) Change in Accured Expenses (2018 - 2026)

Allogene Therapeutics has reported Change in Accured Expenses for 9 years, with the latest figure at -$5.1 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 2.34% year-over-year to -$5.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.4 million (down 201.64% YoY) and the FY2025 annual result came in at -$2.5 million, down 99.68% from the prior year.
• Change in Accured Expenses eased to -$5.1 million in Q1 2026 per ALLO's latest filing, from -$118000.0 in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $5.7 million in Q2 2022 and troughed at -$12.7 million in Q3 2023.
• A 5-year average of -$821000.0 and a median of $286000.0 in 2023 frame the typical range for Change in Accured Expenses.
• The widest YoY moves for Change in Accured Expenses: up 906.99% in 2024, down 1140.51% in 2024.
• Over 5 years, Change in Accured Expenses stood at $3.1 million in 2022, then tumbled by 90.88% to $286000.0 in 2023, then jumped by 906.99% to $2.9 million in 2024, then slumped by 104.1% to -$118000.0 in 2025, then sank by 4222.88% to -$5.1 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$5.1 million, -$118000.0, and $1.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.